Status | Study |
Recruiting |
Study Name: A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors Condition: Relapsed / Recurrent Germ Cell Tumors Date: 2013-09-20 Interventions: Drug: Erlotinib Drug: Sirolimus |
Recruiting |
Study Name: Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Condition: Germ Cell Tumors Date: 2013-06-05 Interventions: Drug: Paclitaxel Drug: Ifosfamide |
Recruiting |
Study Name: A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis Condition: Germ Cell Tumour Date: 2013-01-31 Interventions: Drug: Combination Chemotherapy 4 cycles of: Day 1 Actinomy |
Recruiting |
Study Name: Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors Condition: Intracranial Germ Cell Tumors Date: 2011-08-11 Interventions: Radiation: craniospinal irradiation |
Completed |
Study Name: ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors Condition: Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas) Date: 2010-01-21 Interventions: Drug: Tivantinib (ARQ 197) Capsule, 120 mg, BID (360 mg), approximately 112 days |
Active, not recruiting |
Study Name: Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors Condition: Germ Cell Tumor Central Nervous System Ge Date: 2010-01-13 Interventions: Radiation: Proton Beam radiation Once a day, 5 days a week (Monday-Friday), for 4-8 weeks |
Recruiting |
Study Name: Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis Condition: Germ Cell Tumors Date: 2009-03-16 Interventions: Drug: Paclitaxel 200mg/m2 for |
Completed |
Study Name: Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors Condition: Germ Cell Tumors Date: 2007-12-11 Interventions: Drug: Aprepitant Subjects will |
Terminated |
Study Name: Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors Condition: Germ Cell Tumor Date: 2005-09-08 Interventions: Drug: Cisplatin plus Epirubicin |
Terminated |
Study Name: A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR Condition: Refractory Germ Cell Tumors Expressing EGRF Date: 2005-09-08 Interventions: Drug: ZD1839 Iressa |